Research programme: affimer based PD L1 antagonist - Avacta/LG Chem
Latest Information Update: 08 Aug 2022
At a glance
- Originator Avacta
- Developer Avacta; LG Chem
- Class Antineoplastics; Immunotherapies; Recombinant proteins
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 Jun 2022 Avacta and LG Chem Life Sciences renewed their agreement for the development of additional candidates using the Affimer XT™ serum half-life extension system
- 10 Oct 2021 Avacta and LG Chem Life Sciences expand their agreement for the development of additional candidates using the Affimer XT™ serum half-life extension system
- 07 Oct 2021 Preclinical trials in Cancer in United Kingdom (Avacta pipeline, October 2021)